Measuring Eosinophils to Make Treatment Decisions in Asthma

      The recognition of the association between eosinophils and asthma is not new. Following its discovery by Jones in 1846 and Ehrlich’s identification of its proclivity for aniline dyes to stain its granules, the progress in elucidating the biological characteristics of eosinophils has been described in four phases.

      Gleich GJ. historical overview and perspective on the role of the eosinophil in health and disease. In: Rosenberg H, Lee JJ, eds. Eosinophils in Health and Disease. San Diego, CA: Academic Press; 2012:1-11.

      The first related to the refinement of staining techniques; the second was the description of the association between eosinophils and allergic diseases, including asthma; the third related to the granular chemical and biological features of eosinophils; and the fourth is the current era of the development of strategies to specifically target the molecular pathways that are involved in the development, maturation, and trafficking of eosinophils.
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Gleich GJ. historical overview and perspective on the role of the eosinophil in health and disease. In: Rosenberg H, Lee JJ, eds. Eosinophils in Health and Disease. San Diego, CA: Academic Press; 2012:1-11.

        • Horn R.H.
        • Robin E.D.
        • Theodore J.
        • Van Kessel A.
        Total eosinophil counts in the management of bronchial asthma.
        N Engl J Med. 1975; 292: 1152-1155
        • Brown H.M.
        Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum.
        Lancet. 1958; 2: 1245-1247
        • Lim H.F.
        • Nair P.
        The evolution of sputum cytometry to assess bronchitis.
        Can Respir J. 2013; 20: 415-416
        • D'silva L.
        • Hassan N.
        • Wang H.Y.
        • et al.
        Heterogeneity of bronchitis in airway diseases in tertiary care clinical practice.
        Can Respir J. 2011; 18: 144-148
        • Brightling C.E.
        • Green R.H.
        • Pavord I.D.
        Biomarkers predicting response to corticosteroid therapy in asthma.
        Treat Respir Med. 2005; 4: 309-316
        • O'Byrne P.M.
        The demise of anti IL-5 for asthma, or not.
        Am J Respir Crit Care Med. 2007; 176: 1059-1060
        • Nair P.
        • Pizzichini M.M.
        • Kjarsgaard M.
        • et al.
        Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
        N Engl J Med. 2009; 360: 985-993
        • Haldar P.
        • Brightling C.E.
        • Hargadon B.
        • et al.
        Mepolizumab and exacerbations of refractory eosinophilic asthma.
        N Engl J Med. 2009; 360: 973-984
        • Castro M.
        • Mathur S.
        • Hargreave F.
        • et al.
        • Res-5-0010 Study Group
        Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.
        Am J Respir Crit Care Med. 2011; 184: 1125-1132
        • Wagener A.H.
        • de Nijs S.B.
        • Lutter R.
        • et al.
        External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma.
        Thorax. 2015; 70: 115-120
        • Mukherjee M.
        • Nair P.
        Blood or sputum eosinophils to guide asthma therapy?.
        Lancet Respir Med. 2015; 3: 824-825
        • Pavord I.D.
        • Korn S.
        • Howarth P.
        • et al.
        Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
        Lancet. 2012; 380: 651-659
        • Ortega H.G.
        • Liu M.C.
        • Pavord I.D.
        • et al.
        • MENSA Investigators
        Mepolizumab treatment in patients with severe eosinophilic asthma.
        N Engl J Med. 2014; 371: 1198-1207
        • Castro M.
        • Zangrilli J.
        • Wechsler M.E.
        • et al.
        Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
        Lancet Respir Med. 2015; 3: 355-366
        • Castro M.
        • Wenzel S.E.
        • Bleecker E.R.
        • et al.
        Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
        Lancet Respir Med. 2014; 2: 879-890
        • Smith S.G.
        • Chen R.
        • Kjarsgaard M.
        • et al.
        Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia.
        J Allergy Clin Immunol. 2016; 137: 75-86
        • Ortega H.G.
        • Yancey S.W.
        • Mayer B.
        • et al.
        Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
        Lancet Respir Med. 2016; 4: 549-556
        • Sehmi R.
        • Smith S.G.
        • Kjarsgaard M.
        • et al.
        Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
        Clin Exp Allergy. 2016; 46: 793-802